Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Biotechnology

Healthcare
$398.08 -0.27%

-$1.33 today

Market cap
$9.25B
Beta
-1.06
P/E (TTM)
-46.9
EPS (TTM)
-$10.66
52W Low $276.67High $615.00

Volume 0.64M

Average 0.31M

MDGL Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin widens to -15.5%

Operating margin was -15.5% in Q2 FY2026, up 6.7 pp from a year earlier. On a trailing-twelve-month basis it was -25.1%, up 35.0 pp year over year.

What to watch

Whether operating margin reaches the consensus estimate from 12 analysts of -3.1% for the fiscal year ending Dec 2026, up from -31.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-15.5%+14.3 pp QoQ
Last fiscal yearDec 2025
-31.3%+245.1 pp YoY
LTMJun 2026
-25.1%+35.0 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+6.7 pp+35.2 pp+28.5 pp
1 year+245.1 pp+28.2 pp-216.8 pp
3 years—+49.1 pp—
5 years+62.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-31.3%
Year-over-year change
+245.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How MDGL compares with its peers on the latest reported figures

  • MDGL's LTM Jun 2026 operating margin of -25.1% is the highest of the 5 companies compared; the peer median is -3176.6%.
  • Its year-over-year change of +35.0 pp is the 2nd highest of 5, against a peer median of -1280.3 pp.
MDGL Competitors Peer median
Operating Margin for MDGL and competitors
Company Period LTM level YoY 3-year change
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026-25.1% +35.0 pp—
MAZEMaze Therapeutics, Inc.LTM Mar 2026-670.3% -700.2 pp—
IVAInventiva S.A.FY2025-2921.0% -1860.3 pp-2452.0 pp
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026-3432.2% -3162.2 pp-999.4 pp
ALTAltimmune, Inc.LTM Mar 2026-269216.7% +221748.3 pp-359490.4 pp
VKTXViking Therapeutics, Inc.FY2025— ——
SGMTSagimet Biosciences Inc.FY2025— ——
Peer median (excluding MDGL) -3176.6%-1280.3 pp-2452.0 pp

Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000180.13M958.4M
Cost of Revenue0006.23M56.15M
Gross Profit000173.9M902.26M
Gross Margin———96.5%94.1%
Research & Development205.16M245.44M272.35M236.72M388.53M
Selling, General & Admin37.32M48.13M108.15M435.06M813.83M
Operating Expenses242.48M293.57M380.5M671.78M1.2B
Depreciation & Amortization405K467K527K1.1M1.51M
EBITDA(241.44M)(290.92M)(360.39M)(450.13M)(264.47M)
EBITDA Margin———-249.9%-27.6%
Operating Income(242.48M)(293.57M)(380.5M)(497.88M)(300.1M)
Operating Margin———-276.4%-31.3%
Interest Income363K2.19M19.58M46.65M37.36M
Interest Expense03.96M12.71M14.67M22.31M
Other Income / Expenses636K(1.78M)6.87M31.98M11.81M
Income Before Tax(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Pre-Tax Margin———-258.6%-30.1%
Income Tax Expense00000
Net Income(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Net Margin———-258.6%-30.1%
EPS (Basic)(14.63)(17.23)(19.99)(21.90)(12.85)
EPS (Diluted)(14.63)(17.23)(19.99)(21.90)(12.85)
Weighted Avg Shares16.54M17.14M18.69M21.27M22.43M
Weighted Avg Shares (Diluted)16.54M17.14M18.69M21.27M22.43M

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Intrinsic Alpha fair value

Locked

Current Price

$398.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.